Click here to go to the previous page
Defining Clinical Trial Innovation: Challenges and Opportunities for 2013
Program Code:
145
Date:
Monday, June 24, 2013
Time:
2:30 PM to 4:00 PM
EST
CHAIR
:
Susan K Nunchuck,
PhD,MSN (SCHNON), Senior Clinical Research Associate,
Actelion Clinical Research, United States
Clinical research for 35 years in many roles [clinical specialist in critical care, study coordinator, CRA/LCRA, Manager regulatory Affairs, Director of Clinical Affairs, consultant]. DIA volunteer GCP/QA SIAC Core Commitee, Chair CR SIAC, Nursing Task Force Prior Program Committees.
|
SPEAKER
(S):
Craig H. Lipset,
(SPKNON), Head of Clinical Innovation, Worldwide Research and Development,
Pfizer Inc, United States
Craig Lipset is Head of Clinical Innovation, Development Operations, Worldwide Research & Development at Pfizer. Craig is working across stakeholders to define Pfizer’s vision for the future of clinical trials, and enabling the initiatives and investments to create that future.
|
Andreas Koester, MD,PhD (SPKNON), Vice President, Clinical Trial Innovation, External Alliances, Janssen Pharmaceutical Companies of Johnson & Johnson, United States
Jeffrey S. Kasher,
PhD (SPKNON), Vice President, Clinical Trial: Materials, Implementation and Transformation,
Eli Lilly and Company, United States
Global Clinical Development is responsible for the delivery of all clinical studies and information in support of Eli Lilly and Company's pipeline molecules. The primary responsibility is to patients and healthcare professionals who depend on our products and services.
|
Description
Innovation to improve global health and meet unmet medical needs has challenges and opportunities. Given the regulated and increasingly resource-constrained R&D environment, are there opportunities for innovation to ensure a sustainable future? Panelists will debate and discuss the issues in this interactive forum.
This forum has been developed by the Clinical Research Community.